Published in Pharma Law Weekly, December 28th, 2004
The manufacturers of isotretinoin have licensed these patents with the intention of implementing a new pregnancy risk management system for isotretinoin. The patents are directed to, among other things, Celgene's proprietary S.T.E.P.S. (System for Thalidomide Education and Prescribing Safety) program.
S.T.E.P.S. is the first U.S. Food & Drug...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.